CYP19A1 and breast cancer: The circCNOT2 could be detectable in cell-free RNA from plasma and exhibited clinical potential for aromatase inhibitor therapy because circCNOT2 levels were predictive of progression-free survival time to aromatase inhibitor therapy in advanced BC patients.